

Bibliography

Oncologic Drugs Advisory Committee

02/27/02

1. Balch CM, Buzaid AC, Soong SJ, *et al*: Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. *J. Clin Oncol* 19: 3635-3648. 2001.
2. Kirkwood JM, Strawderman MH, Ernstoff MS, *et al*: Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group trial EST 1684 *J. Clin Oncol* 14:7-17, 1996.
3. Kirkwood JM Adjuvant therapy of high risk resected melanoma: relapse-free and overall survival effects of high-dose interferon alpha 2b in randomized controlled multicenter trials E1684 and E2696 and intergroup trials E1690 and E1694. American Society of Clinical Oncology Educational Book 2001
4. Kirkwood JM, Ibrahim J, Sondak V, *et al*: High- and Low-dose Interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. *J. Clin Oncol* 12: 2444-2458, 2000.
5. Kirkwood JM, Ibrahim JG, Sosman JA *et al*: High dose interferon alfa-2b significantly prolongs relapse free M, *et al*: Postsurgical Adjuvant Therapy for Melanoma: Evaluation of a 3-Year Randomized and overall survival compared with the GM2-KLH/QS21 vaccine in patients with resected stage IIB/III melanoma: Results of intergroup Trial E1694/S9512/C509801. *J. Clin Oncol* 19: 2370-2380. 2001.
6. Kirkwood JM, Ibrahim JG, Lawson DH *et al*: High-Dose Interferon Alfa-2b Does Not Diminish Antibody Response to GM2 Vaccination in Patients With Resected Melanoma: Results of the Multicenter Eastern Cooperative Oncology Group Phase II Trial E2696 *J Clin Oncol* 19: 1430-1436. 2001
7. Rusciani L, Petraglia S, Alotto Trial with Recombinant Interferon- α after 3 and 5 Years of Follow-Up *Cancer* 12:2354-2360. 1997.
8. Cameron DA , Combleet MC, Mackie RM *et al*: Adjuvant interferon alpha 2b in high risk melanoma – the Scottish study. *British Journal of Cancer* 84: 1146-1149. 2001
9. Creagan ET, Dalton RJ, Ahmann DL. *et al*: Randomized, surgical adjuvant clinical trial of recombinant interferon alfa-2a in selected patients with malignant melanoma. *J. Clin Oncol* 13:2776-2783, 1995.
10. Cascinelli N, Belli F, MacKie RM *et al*: Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: a randomised trial. *Lancet*]358:866-9 2001.
11. Grob JJ, Dreno B, De la Salmonier P, *et al*: Randomized trial of interferon alfa-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. *Lancet* 351 (9120): 1905-10. 1998.
12. Hancock BW, Wheatley K, Harrison M, *et al*: Aim high-adjuvant interferon in melanoma (high risk), a United Kingdom Coordinating Committee on Cancer Research (UKCCCR) randomised study of observation versus adjuvant low dose extended duration interferon alpha-2a in high risk resected malignant melanoma. *J. Clin Oncol* 20:349a, 2001.
13. Pehamberger H, Soyer P, Steiner A, *et al*: Adjuvant Interferon Alfa-2a Treatment in resected Primary Stage II Cutaneous Melanoma. *J. Clin Oncol* 16: 1425-1429, 1998.
14. Kleeberg UR, Broucker EB, Lejauns F *et al*: Adjuvant trial in melanoma patients comparing rIFN-alpha to rIFN-gamma to locador to a control group after curative resection of high risk primary (>3mm) or regional lymph node metastasis (EORTEC 18871) *European J. of Cancer* 35: supplement 4 S82, 1999.
15. Wheatley K, Hancock B, Gore M, *et al*: Interferon α as adjuvant therapy for melanoma: a meta-analysis of the randomized trials *J. Clin Oncol* 20: 349a, 2001.